MRNA Stock Plunges 18% After Leaked Melanoma Vaccine Data Misses High Hopes

Investors were awaiting full data from the late-stage trial of intismeran autogene plus Merck’s Keytruda at the European Society for Medical Oncology Congress on October 24.

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stocktwits.com)